Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-03-14 Proxy Solicitation & In…
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for NKMAX. It outlines the date, location, agenda items (including financial statement approval, board appointments, and remuneration limits), and details regarding director and auditor candidates. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their participation/votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification filed by NKMAX regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and the company's compliance status with the KOSDAQ Association's voluntary distribution program. As this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or the voting results, it falls under the general regulatory filing category.
2024-03-14 Korean
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding the cancellation of stock collateral agreements by a major shareholder. It details the resolution of share pledges, the number of shares involved, and the reasons for the cancellation (such as margin calls/forced sales). This type of disclosure is a standard regulatory requirement for listed companies to report changes in major shareholding status and collateral arrangements, falling under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Major Shareholding Notification' (which is for threshold crossings).
2024-03-04 Korean
[기재정정]불성실공시법인지정예고 (공시번복 1건, 공시불이행 4건)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KOSDAQ) regarding a 'Notice of Designation as an Unfaithful Disclosure Corporation' (불성실공시법인지정예고). It details specific instances of delayed disclosures and disclosure reversals by the company NKMAX. Since this is a formal regulatory notification regarding compliance and disclosure obligations, it falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or corporate action categories like M&A or dividends.
2024-03-04 Korean
최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (NKMAX) detailing a 'Stock Collateral Agreement' (주식 담보제공 계약) involving the company's largest shareholder. This type of disclosure is a standard regulatory requirement in Korea for listed companies to report changes in collateralized shares held by major shareholders. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure of a financial arrangement, it is classified as a Regulatory Filing (RNS).
2024-02-28 Korean
[기재정정]불성실공시법인지정예고 (공시번복 1건, 공시불이행 3건)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KOSDAQ) regarding a 'Notice of Designation as an Unfaithful Disclosure Corporation' (불성실공시법인지정예고). It details specific instances of disclosure failures, such as delayed disclosures and contract cancellations. Since this is a formal regulatory announcement regarding compliance and disclosure status that does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2024-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.